Apellis Pharmaceuticals Inc (APLS)
27.75
+0.26
(+0.95%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
-0.02
(-0.07%)
After-Hours: 20:00
Apellis Pharmaceuticals Shareholders Equity (Quarterly): 237.12M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 237.12M |
| June 30, 2024 | 264.33M |
| March 31, 2024 | 266.68M |
| December 31, 2023 | 194.52M |
| September 30, 2023 | 232.27M |
| June 30, 2023 | 345.40M |
| March 31, 2023 | 412.12M |
| December 31, 2022 | 169.87M |
| September 30, 2022 | 307.42M |
| June 30, 2022 | 334.42M |
| March 31, 2022 | 462.24M |
| December 31, 2021 | 198.66M |
| September 30, 2021 | -57.32M |
| June 30, 2021 | -141.49M |
| March 31, 2021 | 51.66M |
| December 31, 2020 | 204.56M |
| September 30, 2020 | 105.84M |
| June 30, 2020 | 232.06M |
| Date | Value |
|---|---|
| March 31, 2020 | 259.00M |
| December 31, 2019 | 34.23M |
| September 30, 2019 | 139.56M |
| June 30, 2019 | 159.09M |
| March 31, 2019 | 224.75M |
| December 31, 2018 | 160.97M |
| September 30, 2018 | 195.95M |
| June 30, 2018 | 229.55M |
| March 31, 2018 | 129.04M |
| December 31, 2017 | 148.94M |
| September 30, 2017 | 12.20M |
| June 30, 2017 | 24.00M |
| December 31, 2016 | 23.79M |
| December 31, 2015 | 34.98M |
| September 30, 2015 | 11.09M |
| June 30, 2015 | 15.55M |
| December 31, 2014 | 13.22M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-141.49M
Minimum
Jun 2021
462.24M
Maximum
Mar 2022
205.68M
Average
232.17M
Median
Shareholders Equity (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 5.413B |
| Ionis Pharmaceuticals Inc | 662.47M |
| EyePoint Pharmaceuticals Inc | 218.73M |
| Cassava Sciences Inc | 166.64M |
| Macrogenics Inc | 120.07M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 901.87M |
| Total Liabilities (Quarterly) | 664.74M |
| Debt to Equity Ratio | 1.907 |
| Current Ratio | 4.36 |
| Net Debt Paydown Yield | -2.04% |